Search results
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
Zacks via Yahoo Finance· 1 year agoRegeneron Pharmaceuticals, Inc. REGN delivered better-than-expected fourth-quarter 2022 results even...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks via Yahoo Finance· 3 weeks agoRegeneron Pharmaceuticals, Inc. REGN delivered lower-than-expected first-quarter 2024 results due to...
Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?
Zacks via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals, Inc. REGN is scheduled to release third-quarter 2022 results on Nov 3,...
If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now
Zacks via Yahoo Finance· 2 years agoFor most investors, how much a stock's price changes over time is important. This factor can impact...
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
Zacks via Yahoo Finance· 1 year agoRegeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2023 results on May 4,...
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Benzinga via Yahoo Finance· 1 year agoRegeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating...
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
Motley Fool· 8 months agoCompanies generally decide to engage in stock splits after their shares have soared to a level that...
Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update
Zacks via Yahoo Finance· 2 years agoEarnings results, along with important regulatory and pipeline updates, continue to keep the biotech...
2 Top Biotech Stocks to Buy in November
Motley Fool· 2 years agoBiotech giants Regeneron Pharmaceuticals (NASDAQ: REGN) and Gilead Sciences (NASDAQ: GILD) are among them. Eylea could lose patent protection as early as...
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
Benzinga via Yahoo Finance· 1 year agoSAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National...